Use of nitric oxide nanoparticulate platform for the treatment of skin and soft tissue infections
Article first published online: 9 MAY 2013
© 2013 Wiley Periodicals, Inc.
Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology
Volume 5, Issue 5, pages 502–514, September/October 2013
How to Cite
Kutner, A. J. and Friedman, A. J. (2013), Use of nitric oxide nanoparticulate platform for the treatment of skin and soft tissue infections. WIREs Nanomed Nanobiotechnol, 5: 502–514. doi: 10.1002/wnan.1230
- Issue published online: 25 SEP 2013
- Article first published online: 9 MAY 2013
- Manuscript Accepted: 18 APR 2013
- Manuscript Revised: 8 MAR 2013
- Manuscript Received: 15 JAN 2013
The incidence of skin and soft tissue infections (SSTI) due to multi-drug resistant pathogens is increasing. The concomitant increase in antibiotic use along with the ease with which organisms develop mechanisms of resistance have together become a medical crisis, underscoring the importance of developing innovative and effective antimicrobial strategies. Nitric oxide (NO) is an endogenously produced molecule with many physiologic functions, including broad spectrum antimicrobial activity and immunomodulatory properties. The risk of resistance to NO is minimized because NO has multiple mechanisms of antimicrobial action. NO's clinical utility has been limited largely because it is highly reactive and lacks appropriate vehicles for storage and delivery. To harness NO's antimicrobial potential, a variety exogenous NO delivery platforms have been developed and evaluated, yet limitations preclude their use in the clinical setting. Nanotechnology represents a paradigm through which these limitations can be overcome, allowing for the encapsulation, controlled release, and focused delivery of NO for the treatment of SSTI. WIREs Nanomed Nanobiotechnol 2013. doi: 10.1002/wnan.1230
Conflict of interest: Co-inventor of hybrid NO-np.
For further resources related to this article, please visit the WIREs website.